Skip to main content
OpenTrials
Completed

NCT Number: NCT05215483

Availability and Advice on Test Uptake During the COVID-19 Pandemic: a Vignette Study.

Lateral Flow Testing (LFT) use for COVID-19 related symptoms continues to rise, despite governmental advice to test at a test facility. In this study we investigate whether 1) adjusting the governmental testing advice will lead to a collective increase of people who test with COVID-19 symptoms and if this leads to a higher strategy sensitivity.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

National Institute for Public Health and the Environment

Bilthoven, Utrecht, 3720 BA, Netherlands

About this study

In an online randomised multi-factorial survey (vignette study) participants are randomised to assess four scenario's. Between subject testing advise is randomised (IV1; 2 levels) and the availability of LFT (IV2; 2 levels). Within subject we asked participants to assess their most likely behaviour on day 1 of symptoms and day 3 of unchanged symptoms (IV3; 2 levels). Corona-related symptoms are randomly presented (IV4; 4 levels) and new incidences of symptoms are presented in additional vignettes describing new months (IV5; 4 levels).

Subjects are asked to immerse themselves in the scenario's before answering what their most likely behaviour would be: a) go to a test facility b) use a LFT c) wait and see or 4) no test. Participants who didn't choose the test facility on day 1 were presented with the same vignette on day 3 with unchanged symptoms, and were asked their most likely behaviour again.

After assessing the scenario's, participants fill in a questionnaire assessing demographics, behavioural determinants related to test behaviour, vaccine status, current symptoms and previous experience with Corona and testing.

The primary outcomes is defined as the average strategy sensitivity over time and therefore the chance of detecting a Covid-infection. Average strategy sensitivity is calculated by converting the choice of testing behaviour into the corresponding sensitivity score (PCR =1, LFT day 1 = .8, LFT day 3 = .7, wait and see and no test = 0), averaged over four scenario's.

Our primary hypothesis is:

  • Adjusting the governmental testing advice will lead to a higher strategy sensitivity.

In follow-up analysis we will explore the following hypothesis:

  • Availability of LFT at home will lead to a higher strategy sensitivity.
  • The type of corona related symptoms (mild or severe) are predictive of the type of test used.
  • When confronted with a new incidence of corona-related symptoms over time, strategy sensitivity will decline.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Participants were recruited from an online research panel representative for the Dutch population.

Inclusion criteria

  • non

Exclusion criteria

  • non

Treatment and study plan

Customised testing advice

Behavioral

Customised advice: With Corona related symptoms, get tested at a test facility. If this isn't possible, use a Lateral Flow test.

Regular testing advice

Behavioral

Government guideline testing advice: "With Corona related symptoms, get tested at a test facility".

LFT available

Behavioral

LFT availability: Enough lateral flow tests available at home

No LFT available

Behavioral

LFT availability: No lateral flow tests available at home

Primary outcomes

  1. Average strategy sensitivity over time: day 1

    Time frame: average strategy sensitivity day 1

    The sensitivity of the test chosen was used to convert each answer: test facility on day 1 = 1, LFT on day 1= 0.8, Wait and see or No test = 0. Sensitivity scores were then averaged over the four scenario's.

  2. Maximum average strategy sensitivity over time

    Time frame: maximum average strategy sensitivity day 1 and 3

    The sensitivity of the test chosen was used to convert each answer: test facility on day 1 or day 3 = 1, LFT on day 1= 0.8, LFT on day 3= 0.7, Wait and see or No test = 0. Sensitivity scores were then averaged over the four scenario's. The highest score of day 1 and day 3 was used to calculate the maximum sensitivity score.

Secondary outcomes

  1. Willingness to test day 1

    Time frame: Day 1

    Willingness to test on day 1 (LFT & PCR =1, no test = 0), averaged over the four scenario's.

  2. Willingness to test - maximum

    Time frame: Day 1 and 3

    Willingness to test on day 1 and 3 (LFT & PCR =1, no test = 0), averaged over the four scenario's.

  3. Type of test chosen day 1

    Time frame: Day 1

    Percentage of testing behaviour (test facility, LFT, Wait and see, No test) on day 1, averaged over the four scenario's.

  4. Type of test chosen day 3

    Time frame: Day 3

    Percentage of testing behaviour (test facility, LFT, Wait and see, No test) on day 3, averaged over the four scenario's.

Sponsors and collaborators

Lead sponsor

National Institute for Public Health and the Environment (RIVM)

Other Gov

Registry information

Official study title

Availability and Advice on Test Uptake During the COVID-19 Pandemic: a Vignette Study on Lateral Flow Testing Policy in the Netherlands.

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Jan 31, 2022
Registry last updated
Jan 31, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.